Ultragenyx Pharmaceutical (RARE) to Release Quarterly Earnings on Thursday

Ultragenyx Pharmaceutical (NASDAQ:RARE) is set to announce its earnings results after the market closes on Thursday, August 1st. Analysts expect the company to announce earnings of ($1.64) per share for the quarter.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.72) by ($0.31). Ultragenyx Pharmaceutical had a negative net margin of 138.58% and a negative return on equity of 425.63%. The company had revenue of $108.83 million during the quarter, compared to the consensus estimate of $116.03 million. During the same quarter last year, the firm posted ($2.33) earnings per share. The company’s quarterly revenue was up 8.3% on a year-over-year basis. On average, analysts expect Ultragenyx Pharmaceutical to post $-6 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Ultragenyx Pharmaceutical Price Performance

RARE traded up $0.39 during trading on Friday, hitting $45.45. 33,664 shares of the stock traded hands, compared to its average volume of 803,951. Ultragenyx Pharmaceutical has a twelve month low of $31.52 and a twelve month high of $54.56. The company has a market cap of $3.78 billion, a price-to-earnings ratio of -5.66 and a beta of 0.56. The business has a 50 day moving average price of $41.41 and a 200 day moving average price of $44.53.

Analyst Ratings Changes

Several research analysts have commented on RARE shares. Wedbush restated a “neutral” rating and set a $45.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Thursday, July 18th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $111.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Tuesday. TD Cowen upped their price target on shares of Ultragenyx Pharmaceutical from $59.00 to $61.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Robert W. Baird upped their price objective on Ultragenyx Pharmaceutical from $68.00 to $72.00 and gave the company an “outperform” rating in a research note on Friday, May 31st. Finally, Stifel Nicolaus raised their price target on shares of Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the company a “buy” rating in a research note on Friday, May 31st. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $86.50.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 9,806 shares of the firm’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $45.00, for a total value of $441,270.00. Following the completion of the sale, the executive vice president now directly owns 57,981 shares in the company, valued at $2,609,145. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 1,737 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $41.10, for a total transaction of $71,390.70. Following the completion of the transaction, the director now owns 7,248 shares in the company, valued at approximately $297,892.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Karah Herdman Parschauer sold 9,806 shares of Ultragenyx Pharmaceutical stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $45.00, for a total value of $441,270.00. Following the transaction, the executive vice president now owns 57,981 shares of the company’s stock, valued at approximately $2,609,145. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,127 shares of company stock worth $536,593. Corporate insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.